corgenix Message Board - Msg: 24090471

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : corgenix

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: RikRichter	11/28/2007 11:55:16 AM
	of 191

I was a little confused about the news released on Monday, November 26th regarding the clinical trial data on AtherOx. In the news release CONX made reference to a preliminary clinical trial involving the AtherOx Test Kit. I requested clairification from CONX's CFO about this reference to the AtherOx Test Kit and whether it differed from the IgG Anti-AtherOx Test Kit that is pending FDA approval. The CFO responded that these are two (2) separate tests and here is the email that I received: "Please see below for a description of the two assays. Neither of the two assays has been cleared by the FDA. “AtherOx” is our trademark name for the patented molecule which consists of an oxidized low density lipoprotein molecule bound to a beta-2-glycoprotein-I molecule (OxLDL-B2GPI). The test to measure AtherOx measures the combined molecule itself and clinical data demonstrates that elevated levels of AtherOx demonstrates an oxidized state of lipoproteins which is a component of the development of cardiovascular disease. “Anti-AtherOx” tests measure antibodies that have been built against the AtherOx molecule. As AtherOx is in essence a non-normal molecule, the body may recognize it as foreign and build antibodies to it just like it would do for any other foreign body including infectious agents. If we measure antibodies to AtherOx in a patient, it shows that the AtherOx molecule has existed for a period of time, long enough for the immune system to start building antibodies. In addition, antibodies to Atherox seem to accelerate the development of atherosclerosis as seen in patients with autoimmune diseases. We believe that the presence of AtherOx in an individual is bad; having anti-AtherOx is worse because it indicates the oxidation has been occurring for a longer period of time and it may accelerate the development of atherosclerosis

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next